The number really did drop. Given the same patients, PREVENT put the average 10-year heart-attack-or-stroke risk at 4.6%, against 9.0% from the old Pooled Cohort Equations — a little over half 1. The old equations were built on Americans recruited between 1960 and 1990, when smoking was higher and blood pressure barely treated, so they overshot by 40 to 50% on a modern population 2. PREVENT was fit on 6.6 million contemporary adults, and it tracks today's outcomes closely in independent testing 3.
Lower is not the same as fine. The threshold moved down with the number. The 2026 cholesterol guideline dropped the level that opens a statin conversation from a 10-year risk of 7.5% to 3% 2. Applying old cutoffs to the new number quietly undertreats: keep the 7.5% line while switching calculators and an estimated 107,000 extra heart attacks and strokes follow over a decade 1.
It looks further ahead. A healthy 35-year-old almost always scores under 3% over ten years, so the old calculator gave clinicians nothing to act on. PREVENT's 30-year number is the one that catches the young adult whose lipids and family history would, left alone, land a heart attack at 58 4.
You can run this at the kitchen table with your last annual physical.
The number starts the conversation about a statin; the decision still belongs to you and a clinician.
The fine print — when to skip it, and what people get wrong
"Lower number, so I'm fine." A 4% score that read "low" before now sits in the treat range under the 3% threshold 2. And a 2% 10-year risk is real at 65 but just a short window at 35 4.
The young-Black-adult gap. Among adults 30 to 39, observed cardiovascular events in Black participants ran roughly double the PREVENT-predicted rate; a low score there is not reassurance 4.
PREVENT is for primary prevention only. If you've had a heart attack, stroke, or established heart disease, the equation doesn't apply — you're on a different pathway 4. It also won't return a meaningful estimate under 30 or over 79.
- 1Diao JA, Shi I, Murthy VL, et al. (2024). Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk Equations. JAMA. link
- 2Grundy SM, Stone NJ, Bailey AL, et al. (2026). 2026 ACC/AHA Guideline on the Management of Dyslipidemia. Circulation. link
- 3Scheuermann B, Brown A, Colburn T, et al. (2024). External Validation of the American Heart Association PREVENT Cardiovascular Disease Risk Equations. JAMA Network Open. link
- 4Khan SS, Matsushita K, Sang Y, et al. (2024). Development and Validation of the American Heart Association's PREVENT Equations. Circulation. link
დაკავშირებული სახელმძღვანელოში (10)
- — A risk calculator only guesses what's in your arteries; the scan looks directly — use it when the estimate is borderline.
- — When the PREVENT number is borderline, the advanced panel can tip the statin decision.
- — PREVENT is the first risk calculator to fold in kidney function — so the eGFR you feed it has to be the accurate one.
- — The standard calculator misses pregnancy, early menopause, and autoimmune risk — know what it leaves out.
- — Your averaged home number is the blood-pressure input this risk calculator actually wants.
- — Your blood pressure is one of the biggest inputs to your overall cardiovascular risk score.
- — The calculator decides whether to treat; these are the tools once the answer is yes.
- — Faded morning erections are an early vascular warning. Take it further and put real numbers on your heart risk.
- — A risk percentage only means something once you can read what a treatment actually changes.
- — Smoking status is a direct input to the PREVENT heart-risk score. Quitting is one of the fastest ways to drop the number it gives you.
AHA PREVENT Calculator
The PREVENT calculator itself is free and publicly hosted. The eight required inputs that are not patient-known (cholesterol panel, eGFR, BMI) are produced by a routine annual physical, typically bundled into insurance-covered preventive care. Marginal cost to run PREVENT given a recent physical is effectively zero.
Reading the eleven inputs off a lab report and entering them into the calculator takes under five minutes once a year. No ongoing behavioural change is required by the calculator itself — any downstream effort (taking a statin, changing diet) belongs to the intervention the calculator points toward.
Derived on 3.28M U.S. adults across 25 contemporary cohorts and externally validated on 3.33M adults across 21 additional datasets, with sex-specific median C-statistics of 0.79 (women) and 0.76 (men) for total CVD (Khan 2024). Independent NHANES external validation reported C 0.890 for 10-year CVD mortality, outperforming PCE on both discrimination and calibration (Scheuermann 2024). Formally adopted by the 2025 ACC/AHA Hypertension Guideline and the 2026 ACC/AHA Dyslipidemia Guideline (Grundy 2026). Not 5 because long-term prospective outcome data comparing PREVENT-guided vs PCE-guided clinical pathways does not yet exist.
The calculator is informational, not therapeutic — its longevity effect is mediated entirely through the statin and antihypertensive decisions it gates. Better-calibrated risk numbers in the contemporary U.S. population should translate to better-targeted primary-prevention pharmacotherapy, but the Diao 2024 JAMA projection found that at unchanged thresholds, replacing PCE with PREVENT would produce ~107,000 additional MIs and strokes over 10 years, partly offset by ~57,800 fewer incident diabetes cases (Diao 2024). The net longevity gain is real but small and contingent on guideline-threshold recalibration; the 2026 dyslipidemia guideline addressed this by moving statin initiation from 7.5% to 3% (Grundy 2026).